nature portfolio

Corresponding author(s):	Shotaro Chubachi
Last updated by author(s):	Feb 1, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

_					
$\langle \cdot \rangle$	t a	t۱	ıci	ш	CS
.)			וכו		t >

For	all statistical an	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.			
n/a	Confirmed				
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
	🔀 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
	A description of all covariates tested				
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>				
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
\square Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated					
	•	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.			
Software and code					
Poli	cy information	about <u>availability of computer code</u>			
Da	ata collection	No software was used.			
Da	ata analysis	No software was used.			
		g custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and			

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The data that support the findings of this study are available from the corresponding author, SC, upon reasonable request.

Human rese	arch par	ticipants					
Policy information a	about <u>studie</u>	s involving human research participants and Sex and Gender in Research.					
Reporting on sex and gender		Information on biological and social gender was not collected or used in the analysis.					
Population characteristics		See above.					
Recruitment		All outpatients were consecutively recruited and cases with consent were entered.					
Ethics oversight		The Keio University and Nihon Kokan Hospital.					
Note that full informa	tion on the ap	proval of the study protocol must also be provided in the manuscript.					
	_:£:						
Field-spe		<u> </u>					
	ne below tha	t is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.					
Life sciences	ho document w	Behavioural & social sciences Ecological, evolutionary & environmental sciences ith all sections, see nature.com/documents/nr-reporting-summary-flat.pdf					
roi a reference copy or t	ne document w	titi ali sections, see <u>nature compuocumentsym-reporting-summary-nat.pur</u>					
Life scier	nces s	tudy design					
All studies must dis	close on the	se points even when the disclosure is negative.					
Sample size	We recruited	/e recruited patients consecutively as much as possible on the cohort study, so we could not calculate the number of sample size.					
Data exclusions	Exclusion cri	xclusion criteria were pre-established and other data were not excluded from the analyses.					
Replication	There was no	here was no replication study in our study.					
Randomization	Because of t	ne cohort study, no randomization was performed.					
Blinding	Because of the cohort study, blinding was not performed.						
Reportin	g for «	specific materials, systems and methods					
		rs about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,					
system or method list	ed is relevant	to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.					
Materials & exp	perimenta	systems Methods					
n/a Involved in th	e study	n/a Involved in the study					
Antibodies		ChIP-seq					
Eukaryotic cell lines		Flow cytometry					
	Palaeontology and archaeology MRI-based neuroimaging						
Animals and other organisms							
	Clinical data						
X Dual use re	esearch of con	cern					
Clinical data							
Policy information a	·	l studies the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.					
Clinical trial regist		research protocol was approved by the respective human ethics committees of the two institutions at Keio University School of dicine (reference number: 2009-0008), and Nihon Kokan Hospital (reference number: 2015-2).					

Keio University School of Medicine and Nihon Kokan Hospital

Study protocol

Data collection

Patients were enrolled from April 2010 to December 2012.

Outcomes

Association of lung physiological abnormality and body composition with representing the sum of apnea and hypopnea events.